Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 20.52% | 23.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.21% | -0.37% | |||
| Operating Income | 19.21% | 0.37% | |||
| Income Before Tax | 19.14% | -0.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.14% | -0.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.14% | -0.42% | |||
| EBIT | 19.21% | 0.37% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 19.63% | 0.93% | |||
| Normalized Basic EPS | 19.60% | 0.97% | |||
| EPS Diluted | 19.63% | 0.93% | |||
| Normalized Diluted EPS | 19.60% | 0.97% | |||
| Average Basic Shares Outstanding | 0.60% | 1.37% | |||
| Average Diluted Shares Outstanding | 0.60% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||